{
    "clinical_study": {
        "@rank": "21655", 
        "arm_group": [
            {
                "arm_group_label": "T-R (Test-Reference drug)", 
                "arm_group_type": "Experimental", 
                "description": "DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period"
            }, 
            {
                "arm_group_label": "R-T (Reference-Test drug)", 
                "arm_group_type": "Experimental", 
                "description": "Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single-blind, randomized, comparative, phase I study to evaluate the tolerability,\n      safety and pharmacokinetic characteristics of human chorionic gonadotropin between two\n      recombinant hCG products named DA-3803 injection and ovidrel liquid injection, in healthy\n      subjects. The subjects will injected with these two injections at the the 21day-interval of\n      time and their conditions including vital signs, blood, clinical examination will be\n      carefully observed."
        }, 
        "brief_title": "A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803", 
        "completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Infertility", 
            "Induction of Ovulation"
        ], 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  No medical history relating to the alimentary system, liver system, heart system,\n             haematological disease\n\n          -  Ideal body weight +/- 20%\n\n        Exclusion Criteria:\n\n          -  acute disease within 28 days\n\n          -  medical history that might affect the absorption, distribution, secretion, metabolism\n             of drugs\n\n          -  metrectomy surgery\n\n          -  desexualization\n\n          -  tubal ligation\n\n          -  menopause\n\n          -  pregnancy\n\n          -  not able to use contraception\n\n          -  drink alcohol more than 14 units/week\n\n          -  smoker who smokes 10 or more cigarettes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851512", 
            "org_study_id": "DA3803_HCG_I"
        }, 
        "intervention": [
            {
                "arm_group_label": "T-R (Test-Reference drug)", 
                "intervention_name": "T-R (Test-Reference drug)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Drug: DA-3803 (Test drug)", 
                    "Drug: Ovidrel liquid injection (Referecne drug)"
                ]
            }, 
            {
                "arm_group_label": "R-T (Reference-Test drug)", 
                "intervention_name": "R-T (Reference-Test drug)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Drug: Ovidrel liquid injection (Referecne drug)", 
                    "Drug: DA-3803 (Test drug)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Chorionic Gonadotropin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2013", 
        "number_of_arms": "2", 
        "official_title": "Single-Blind, Randomized, Comparative, Phase I Study to Evaluate the Tolerability, Safety, and Pharmacokinetic Characteristics of Human Chorionic Gonadotropin Between Two Recombinant hCG Products, DA-3803 Injection and Ovidrel Liquid Injection, in Healthy Subjects", 
        "overall_official": [
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Ji-Young Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Kyoung-Ah Kim, Ph.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Un Jip Kim, M.D., Ph.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Soo Kyung Kim, M.D., Ph.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Hyun Tae Park, M.D., Ph.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Examine the following:\nMaximum blood concentration\nTravel time of maximum blood concentration\nhalf time t(1/2)\nClearance\nVolume of distribution", 
            "measure": "Concentration in serum of hCG examined by non-compartmental analysis", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851512"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}